Key Points
- CEO Kevin Lee sold 5,967 shares on April 2 at an average $4.91 for $29,297.97 and another 1,716 shares on April 6 (~$5.05), totaling 7,683 shares sold to cover tax withholding on vested equity and leaving him with 613,029 shares (≈$3.01M), a 0.96% ownership decline.
- Other insiders—including the COO and CFO—also sold shares under tax‑related or 10b5‑1 filings, a disclosure that the company says is tax‑driven but which may still temper investor sentiment.
- Operationally, Bicycle Therapeutics posted a revenue beat ($47.96M vs. $7.08M) and EPS of −$0.29 (better than estimates) but remains unprofitable with negative margins, and analysts hold a mixed consensus of “Hold” with an average price target of $14.50.
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC - Get Free Report) CEO Kevin Lee sold 5,967 shares of the company's stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $4.91, for a total value of $29,297.97. Following the transaction, the chief executive officer directly owned 613,029 shares of the company's stock, valued at $3,009,972.39. This represents a 0.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Kevin Lee also recently made the following trade(s):
- On Monday, April 6th, Kevin Lee sold 1,716 shares of Bicycle Therapeutics stock. The stock was sold at an average price of $5.05, for a total value of $8,665.80.
Bicycle Therapeutics Price Performance
BCYC stock opened at $4.89 on Tuesday. The stock has a market capitalization of $340.88 million, a P/E ratio of -1.55 and a beta of 1.65. The business has a 50-day moving average of $5.33 and a 200-day moving average of $6.57. Bicycle Therapeutics PLC Sponsored ADR has a fifty-two week low of $4.24 and a fifty-two week high of $9.55.
Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last posted its quarterly earnings data on Wednesday, March 18th. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($1.00) by $0.71. The company had revenue of $47.96 million during the quarter, compared to analysts' expectations of $7.08 million. Bicycle Therapeutics had a negative return on equity of 33.21% and a negative net margin of 301.66%. Equities analysts expect that Bicycle Therapeutics PLC Sponsored ADR will post -3.06 EPS for the current year.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of the stock. Assetmark Inc. lifted its position in shares of Bicycle Therapeutics by 74.9% in the third quarter. Assetmark Inc. now owns 3,625 shares of the company's stock valued at $28,000 after buying an additional 1,552 shares during the last quarter. Man Group plc lifted its position in shares of Bicycle Therapeutics by 4.8% in the fourth quarter. Man Group plc now owns 42,860 shares of the company's stock valued at $303,000 after buying an additional 1,969 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in shares of Bicycle Therapeutics by 1.6% in the second quarter. The Manufacturers Life Insurance Company now owns 140,492 shares of the company's stock valued at $976,000 after buying an additional 2,243 shares during the last quarter. Ameriprise Financial Inc. lifted its position in shares of Bicycle Therapeutics by 21.7% in the third quarter. Ameriprise Financial Inc. now owns 14,972 shares of the company's stock valued at $116,000 after buying an additional 2,668 shares during the last quarter. Finally, Clearstead Advisors LLC lifted its position in shares of Bicycle Therapeutics by 234.2% in the fourth quarter. Clearstead Advisors LLC now owns 4,655 shares of the company's stock valued at $33,000 after buying an additional 3,262 shares during the last quarter. 86.15% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several research firms have recently weighed in on BCYC. Needham & Company LLC reduced their price objective on Bicycle Therapeutics from $24.00 to $15.00 and set a "buy" rating for the company in a research report on Wednesday, March 18th. Weiss Ratings reissued a "sell (e+)" rating on shares of Bicycle Therapeutics in a research report on Monday, December 22nd. Morgan Stanley reissued a "sell" rating and set a $13.00 price target on shares of Bicycle Therapeutics in a research report on Tuesday, March 17th. Truist Financial set a $8.00 price target on Bicycle Therapeutics in a research report on Tuesday, March 17th. Finally, Oppenheimer reduced their price target on Bicycle Therapeutics from $44.00 to $36.00 and set an "outperform" rating for the company in a research report on Wednesday, March 18th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have given a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $14.50.
Get Our Latest Analysis on Bicycle Therapeutics
More Bicycle Therapeutics News
Here are the key news stories impacting Bicycle Therapeutics this week:
- Neutral Sentiment: Multiple executives sold stock to cover tax withholding on vested awards — CEO Kevin Lee sold a total of 7,683 shares across April 2 and April 6 (average prices ~$4.91–$5.05), COO Jennifer Scott Perry sold 1,408 shares under a pre‑arranged 10b5‑1 plan, and CFO Travis Thompson sold 901 shares. Sales were disclosed on SEC Form 4s and described as tax‑related rather than opportunistic cash‑outs, which mutes but does not eliminate negative investor reaction to visible insider selling. CEO Form 4 COO Form 4 CFO Form 4
- Neutral Sentiment: Analyst coverage remains mixed and the consensus is a "Hold" from the group of brokers covering BCYC (MarketBeat notes the consensus). A hold consensus provides limited near‑term buying pressure and can reinforce cautious sentiment following insider sales. Analyst Consensus Article
About Bicycle Therapeutics
(
Get Free Report)
Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company's core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.
Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
